Our key clinical areas of focus are currently respiratory, gastrointestinal, transplant diagnostics and insect-borne disease. Through our exceptional technical expertise we are continually working to expand our product ranges and specialties to meet unmet needs in infectious diseases.


The COVID-19 pandemic has taught us that identifying the right seasonal respiratory testing solutions and ensuring healthcare providers have the right tools to support optimal treatment is more critical than ever. Prioritisation of seasonal respiratory diagnostics, especially where winter diseases are prevalent, remains essential to governmental policies and health economies worldwide and we have developed one of the world’s first approved respiratory test panels that differentiates between COVID-19 and other common winter respiratory viruses. Our ongoing work will deliver new products in the respiratory diagnostic markets as Novacyt continues to drive change in how we test for infectious diseases worldwide.


Each year there are more than 6 billion gastrointestinal (GI) infections diagnosed worldwide. Developing countries, where access to reliable testing is limited, are particularly impacted. Molecular diagnostics can offer valuable insights when a patient is suspected of suffering from a GI infection; or if a patient reports unexplained symptoms in their gut. We provide simple and easy-to-use test solutions, closer to the patient, which help to speed up diagnosis and provide vital information on patients’ health, ultimately enabling faster treatment and potentially reducing healthcare costs. At Novacyt, we already provide diagnostic solutions for a wide range of gastrointestinal infections, and are continuing to invest in this area to broaden our offering.

For information on our gastrointestinal diagnostic products, please contact us.


Transplant patients are vulnerable to infection due to receiving immunosuppressive agents which can disrupt the immune function and cause viral reactivation, particularly in the first six months after surgery. Transplantation diagnostics involve pre-transplant screening and post-transplant monitoring. We offer varying solutions for transplant diagnostics through PCR and other molecular assays. In particular, we provide diagnostics for the three main transplant diagnostic targets, cytomegalovirus (CMV), Epstein-Barr virus (EBV) and BK virus (BKV) as well as other common infections, including HSV1/2, HHV6, HHV8, Adenovirus, and JC virus (JCV).

For information on our transplant diagnostic products, please contact us.

Insect-borne disease

Insect-borne or vector-borne diseases are emerging or re-emerging in many geographical areas, especially in tropical and subtropical regions, and they disproportionately affect the poorest populations. The emergence of these diseases is starting to cause concern in terms of both public health threats and economic losses. Besides vector control, the WHO has urged other medical organisations to provide technical support to manage cases and outbreaks. Novacyt has established relationships with aid agencies and NGOs and we are developing diagnostic tools in this area to provide rapid, accurate results.

For information on our insert-borne disease diagnostic products, please contact us.

Future interests

We are also considering additional unmet needs in infectious diseases including sexually transmitted infections (STI), urinary tract infections (UTI), hospital acquired infections, meningitis/encephalitis and sepsis.

If you are interested in partnering with Novacyt on any business development opportunities in these sectors please do get in touch.